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Abstract 
Cyclic guanosine 3’,5’-monophosphate (cGMP)-dependent protein kinase (PKG) 
activates a signaling pathway that leads to vascular smooth muscle cell relaxation, a 
process that reduces blood pressure.  This enzyme consists of a dimerization domain, 
autoinhibitory domain, regulatory domain, and catalytic domain1.  PKG is activated by 
cGMP binding to two binding sites of the regulatory domain.   In order to study how each 
of these two binding sites, A and B, contributes to PKG activation, a mutant that knocked 
out cGMP binding to the B site, PKG Iα E292A, was expressed in Sf9 cells and purified 
to apparent homogeneity.  Despite the presence of this mutation, the affinity for cGMP 
determined by surface plasmon resonance (SPR) was unchanged.  The mutant still 
displayed cGMP dependent activation.  In addition to these cGMP-binding sites, the 
regulatory domain contains a switch helix motif that provides a place for crosstalk 
between the PKG protomers2.  It is not well known how this motif affects cyclic 
nucleotide binding.  In order to determine this, cGMP binding was compared between a 
regulatory domain construct containing the switch helix and one without the switch helix, 
expressed and purified in E. coli.  The presence of the switch helix hindered cyclic 
nucleotide binding to the regulatory domain.   
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Introduction 
 Blood vessels constrict and dilate in response to various stimuli, directing blood 
flow throughout the body.  The protein cyclic guanosine 3’,5’-monophosphate (cGMP)-
dependent protein kinase (PKG), located in the smooth muscle layer of blood vessels, is 
an important regulator of vascular relaxation.  There are two isoforms of PKG expressed 
in vascular smooth muscle from the prkg1 gene: Iα and Iβ3.  PKG I isoforms 
phosphorylate a number of intracellular proteins such as myosin/phosphatase-targeting 
subunit (MYPT1), calcium-dependent large conductance calcium-activated potassium 
channel (BKCa), vasodilator-stimulatory protein (VASP), and inositol 1,4,5-triphosphate 
receptor-associated PKG substrate (IRAG)4,5.  Phosphorylation of these targets by PKG I 
culminating in dephosphorylation of myosin light chain (MLC) and cytoskeletal 
rearrangement results in vascular relaxation (Figure 1). 
 
 
Figure 1: Target substrates of PKG I in vascular smooth muscle cells5.  PKG I activation by cGMP 
results in phosphorylation of target substrates.  The culmination of this signaling cascade leads to a 
decrease in intracellular calcium, rearrangement of the actin/myosin cytoskeleton, resulting in vascular 
smooth muscle relaxation. 
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PKG I is a homodimer consisting of a dimerization/docking (DD) domain, an 
autoinhibitory domain (AI), a regulatory domain, and a catalytic domain1.  The 
dimerization domain is parallel leucine zipper (Figure 2).  The regulatory domain 
contains two cGMP binding sites: the high-affinity A site and low-affinity B site.  Cyclic 
GMP binds to the regulatory domain in a cooperative manner1.  The A site binds with 
equal affinities to cyclic adenosine monophosphate (cAMP) and cGMP, whereas the B-
site has a higher affinity for cGMP2.  When PKG is fully occupied with cGMP, it results 
in a conformational change that exposes the catalytic domain, allowing PKG to 
phosphorylate target substrates6.  The two isoforms expressed in smooth muscle, Iα and 
Iβ, only differ in their dimerization and autoinhibitory domains6.  They are completely 
identical from the start of the regulatory domain onward.  This research will specifically 
focus on the Iα isoform.  
 
 
Figure 2: The structure of PKG I.  The domains include the dimerization/docking domain (DD), 
autoinhibitory domain (AI), the regulatory domain consisting of A and B cGMP binding sites, the switch 
helix (SW), and the catalytic domain. 
  
The FGE motif, which is found in the phosphate binding cassette (PBC) is highly 
conserved in cyclic nucleotide binding sites (Figure 3)1.  The regulatory domain contains 
a highly conserved glutamate residue that binds to the 2’ hydroxyl group of the ribose 
sugar in cyclic nucleotides7.  The charged carboxylate group of this residue is thought to 
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be important in the PKG-cyclic nucleotide interactions by forming a hydrogen bond with 
the ribose8. This motif is found both in the A and B site of PKG Iα. 
 
 
Figure 3: Structure of the cyclic nucleotide binding domains in PKG I4.  (A) Sequence alignment 
showing conservation of the FGE motif (in the red box) in the phosphate-binding cassette (PBC).  The 
mutated residue is indicated with an arrow.  (B) Key residues that mediate cyclic nucleotide binding.  Two 
of these residues are R176 bound to the phosphate group and E167 bound to ribose.  The A site is pictured 
with cAMP, however, the same interaction occurs in the B site.  The interaction that will be interrupted is 
indicated by the red box. 
 
The first objective of this research was to determine the contribution of the A and 
B site on PKG Iα activation.  To address this, we expressed the PKG Iα mutant E292A.  
Glutamate 292 is located in the B site within the FGE motif.  We anticipated the PKG Iα 
E292A mutant would disrupt cyclic nucleotide binding to the B site.  This allowed us to 
determine the contribution of the B site on PKG Iα activation.  We assessed cGMP 
binding to the construct via surface plasmon resonance (SPR) and acetonitrile 
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precipitation.  We also compared its activity to wild type PKG by in vitro 
phosphotransferase assays. 
The second objective of this research was to determine the contribution of the 
switch helix on cyclic nucleotide binding to the regulatory domain.  The regulatory 
domain of PKG Iα consists of the high affinity A site, low affinity B site, and the switch 
helix (Figure 4)1.  The switch helix portion of the enzyme acts a second domain where 
crosstalk can occur between monomers.  The switch helix of one monomer is able to 
interact with the other monomer to form a second area where dimerization can occur. 
 
 
Figure 4: Crystal structure of the regulatory domain of PKG I with switch helix interactions1.  (A) 
Crystal structure of the regulatory domain of one PKG I monomer with the A and B cGMP binding sites as 
well as the switch helix motif.  (B) The interaction between the switch helix motif of one monomer and the 
B site of the other monomer creates a second dimerization site. 
 
The switch helix acts as an additional site where interaction between protomers is 
present, which could affect cyclic nucleotide binding to the B site.  The switch helix 
motif acts as a hydrophobic “knob” that docks into the hydrophobic “nest” on the B site 
of the opposing protomer (Figure 5)2.  The nest exists in the B site of each protomer.  The 
proximity of this motif to the cGMP-binding site could affect cyclic nucleotide binding.  
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Understanding the interactions between cGMP and the regulatory domain with the switch 
helix would provide a clearer picture of how this feature affects the regulation of PKG Iα.   
 
 
Figure 5: Structure of the knob-nest feature of PKG Iα2.  (A) The nest structure with cGMP binding site 
indicated.  (B) The knob of one protomer bound in the nest of the opposing one. 
 
In order to study the contribution of the switch helix, two constructs of the PKG 
Iα regulatory domain were expressed: 78-326 (-SW) and 78-356 (+SW) (Figure 6).  
Cyclic nucleotide binding to these constructs was assessed by SPR. Attempts were made 
to crystallize the regulatory domain without the switch helix (PKG Iα 78-326) in the 
presence of cGMP for x-ray crystallography.  The goal of this was to compare the 
structure of PKG Iα 78-326 to the previously crystallized PKG Iα 78-356 in order to 
elucidate the affect of the switch domain on the cyclic nucleotide binding domain2.  
 
 
Figure 6: Structure of the regulatory domain constructs.  The top construct, PKG Iα 78-326, contains 
the A and B sites.  The bottom construct, PKG Iα 78-356, contains these sites as well as the switch helix 
domain. 
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Materials and Methods 
 Two types of cells were used for expression in these experiments.  Rosetta 
(DE3)pLysS Escherichia coli (E. coli) will be used for expressing the segments of protein 
containing only the regulatory domain.  Since these cells are already competent, they will 
more easily take up the plasmid DNA.  This particular type of E. coli has more codons 
that can be used than typical bacterial cells (EMD Millipore).  For the full length PKG 
expression, Sf9 cells will be used.  These cells are derived from the Spodotera frugiperda 
cell line (Invitrogen).   
Isolating Plasmid DNA Stocks 
New plasmid DNA stocks were made from previously cloned plasmid stocks 
containing DNA segments for parts of the protein PKG Iα.  The plasmids used were PKG 
Iα 78-356•pH6HTN and PKG Iα 78-326•pRSET A.  They expressed protein segments 
bound to a hexahistidine tag (His-tag).  These plasmids were transformed into TOP10 E. 
coli cells and colonies were selected with ampicillin (AMP) and chloramphenicol (CHL).  
The bacteria had to be restreaked onto new plates in order to get single colonies.  Single 
colonies were suspended in Luria Broth (LB) with AMP and CHL.  The plasmids were 
purified using a Mini Prep Kit (Qiagen).   
Protein Expression and Extraction 
 The constructs PKG lα 78-356•pH6HTN and PKG Iα 78-326•pRSET A were 
used for the expression.  These protein segments include the regulatory domain of PKG 
1α with and without the switch helix domain respectively.  Bacterial growth was 
determined by OD600.  For the expression, Rosetta E. coli were transformed with the 
plasmid DNA stocks and selected with AMP and CHL.  Single, transformed colonies 
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from these plates were transferred to liquid media to grow starter cultures. The liquid 
media used was LB with 25 µg/mL CHL and 200 µg/mL carbenicillin (CARB).  CARB 
was used in place of AMP in the liquid media, as it does not break down as readily.  The 
bacteria for the expressions were grown at 37˚C and the induction phase was done at 
25˚C. 
 An expression trial of both PKG lα 78-356 and PKG Iα 78-326 was started using 
50 mL starter cultures with both constructs.  The starter culture samples were diluted 3:40 
into the four 40 mL refresh cultures, two for each construct.   The PKG lα 78-
356•pH6HTN flasks were induced at an OD600 of about 0.9 and the PKG Iα 78-
326•pRSET A flasks were induced at an OD600 of about 0.5.  One of the PKG Iα 78-
356•pH6HTN flasks and one of the PKG Iα 78-326•pRSET A flasks were induced with 
0.5 mM IPTG.  The other two flasks were induced with 1 mM IPTG.  Samples (1mL) 
were taken at 0, 1, 2, and 3 hours as well as the next morning.  Analysis with SDS-PAGE 
showed evidence of protein in the PKG Iα 78-356•pH6HTN samples, but not in the PKG 
Iα 78-326•pRSET A samples. 
The first full expression was of the PKG Iα 78-356•pH6HTN construct based on 
the test expression.  A 7 mL starter culture was used.  At OD600 0.454, the starter culture 
was diluted 1:500 into 1 L of LB with CHL and CARB.  The OD600 of the 1 L of media 
was allowed to reach 0.771 before it was induced with 1 mM IPTG.  The induction 
period was 3 hours at 25˚C.  The samples from before and after induction showed protein 
expression.  After 3 hours, the cells were collected by centrifugation and resuspended in 
lysis buffer with 300 mM NaCl and 5 mM TES pH 7.4.   
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In order to extract protein from the PKG Iα 78-356 pellet cells were lysed using a 
French Press at over 1000 PSI.  The cells were lysed in the presence of a protease 
inhibitor cocktail of 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, 
phosphoramidon, bestatin, E-64, leupeptin, aprotinin, and pepstatin.  The cell fragments 
were removed using centrifugation at 26000xg and filtration.  The remaining fraction was 
applied to a Bio-Scale Mini Profinity Nickel IMAC cartridge (Bio-Rad).  The column 
bound to the His-tags on the protein and isolated it from the rest of the cell material.  The 
protein was eluted from the column using a Profinia Protein Purification System (Bio-
Rad).  A midwash buffer with 500 mM NaCl, 20 mM Imidazole, and 5 mM TES pH 7.4 
was used to wash away anything not tightly bound to the column.  An elution buffer with 
300 mM NaCl, 250 mM Imidazole, and 5 mM TES pH 7.4 was used to release the 
protein from the column.  The eluted protein was dialyzed for 2 hours and then overnight, 
each time at 4˚C in 2 L dialysis buffer with 100 mM NaCl, 1 mM TCEP, and 50 mM 
MES pH 6.9 to remove the excess imidazole groups from the protein.  A final dialysis 
was done in 1 L of dialysis buffer with 10% glycerol.  The protein was concentrated to 
6.59 mg/mL using a spin concentrator tube with a molecular weight cut off of 10 kDa.  
The concentrated protein was separated into aliquots, frozen in liquid nitrogen, and stored 
at -80˚C. 
The second full expression was of the PKG Iα 78-326•pRSET A construct.  The 
50 mL starter culture, which was grown up to OD600 0.831, was diluted 1:500 into 1 L of 
LB with CHL and CARB.  Once the OD600 of the 1 L of media had reached 0.771, the 
flask was induced with 0.1 mM IPTG.  This was incubated at 25˚C overnight.  The cells 
were collected and frozen in liquid nitrogen as in the previous expression.  This was 
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extracted using a French Press as it was done previously.  The protein was at a 
concentration of 0.812 mg/mL in 15 mL.  It was dialyzed twice in 2 L dialysis buffer, 
then in 1 L of dialysis buffer with 10% glycerol.  The protein was concentrated to 4.99 
mg/mL using a spin concentrator tube with a molecular weight cut off of 10 kDa.  This 
was separated into aliquots, frozen in liquid nitrogen, and stored at -80˚C.   
SDS-PAGE and Western Blot 
The sample pellets from each expression were lysed using lysis buffer with 150 
mM NaCl, 1 mM EDTA, 1% Igepal, and 50 mM Tris pH 8. The protein content from 
these samples was then analyzed using sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis (SDS-PAGE) to determine whether the desired segment of PKG-Iα was 
being produced.  The analysis was done with 12% Tris-glycine polyacrylamide gels.  In 
order to analyze the results of the electrophoresis, the gels were either analyzed with 
Western Blot or stained with Instant Blue (C.B.S. Scientific).  For Western Blotting, the 
gels were transferred to a polyvinylidene fluoride (PVDF) membrane at 100V for 1 hour 
using a transfer buffer with 12.5 mM Tris, 96 mM Glycine, 0.05% SDS, and 20% 
methanol. 
Crystallography 
 PKG Iα 78-326 was crystallized in the presence of cGMP.  Four molar 
equivalents of cGMP were mixed with the protein.  The sample was 715 µL of protein at 
a concentration of 4.24 mg/mL after filtration.  This equated to 93.7 nmol of protein, so 
3.74 µL of 100 mM cGMP was added to the protein.  This mixture was then concentrated 
to 12.6 mg/mL, separated into aliquots, frozen in liquid nitrogen, and stored at -80˚C.  A 
crystal screen was prepared with Hampton Research Index Kit HR2-144.  A 1:1 drop 
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ratio and 200 µL wells were used.  All of the trays were incubated at 20˚C and observed 
periodically. 
 The plate was observed under a microscope and two conditions showed needles.  
These two conditions were seen as the most promising, so they were used as the basis for 
further optimization.  They were condition 15 from the screen, 0.5 M magnesium formate 
dehydrate with 0.1 M HEPES pH 7.5, and condition 16, 0.3 M magnesium formate 
dehydrate with 0.1 M Tris pH 8.5.  These same conditions were repeated in 5 wells each 
to ensure the results could be duplicated, and needles were again found in each of these 
conditions. 
 A screen was done with concentrations of magnesium formate dehydrate ranging 
from 0.1 M to 0.8 M with drop ratios of 1:1, 1:2, and 2:1 (Supplemental Figure 1).  
Concentrations of magnesium formate dehydrate ranging from 0.1 M to 0.4 M were 
tested with 5%, 15%, and 25% PEG 3350.  The buffer used for this screen was 0.1 M Tris 
pH 8.  
 Another screen of the magnesium formate dehydrate concentrations ranging from 
0.1 M to 0.8 M with drop ratios of 1:1, 1:2, and 2:1 was done (Supplemental Figure 2).  
This time, each was replicated with 0.1 M HEPES pH 7.5 and 0.1M Tris pH 8.5 as the 
buffers.  The original conditions from the index screen, solutions 15 and 16, were plated 
as references.   
 The fourth plate done was a pH and magnesium formate screen (Supplemental 
Figure 3).  Concentrations of magnesium formate dehydrate ranging from 0.1 M to 0.8 M 
were tested with pH ranging from 6.5 to 8.5.  The buffers used, which were all at 0.1 M, 
were MES pH 6.5, MES pH 7, HEPES pH 7.5, Tris pH 8, and Tris pH 8.5. 
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Sf9 Expression and Extraction 
 Site directed mutagenesis was used to create a mutated PKG Iα gene.  This was 
accomplished using primers: 5’-GGA AAA GGA GAT TGG TTT GGA GCG AAA 
GCC TTG-3’ and 5’-TTC CCC CTG CAA GGC TTT CGC TCC AAA CC-3’.  The Bac-
to-Bac Baculovirus System was used for this process (Invitrogen).  DH10Bac bacterial 
cells were transformed with the gene encoding for the entire PKG Iα protein with the 
glutamate amino acid at position 292 mutated to an alanine amino acid (PKG Iα E292A).  
The bacteria were grown on a plate with kanamycin, gentamycin, tetracylin, IPTG, and x-
gal (KGTIX).  This was allowed to incubate at 4˚C until a clear difference could be seen 
between blue and white colonies.   
 Three white colonies and one blue colony were selected from the original plate 
and restreaked onto new KGTIX plates to confirm plasmid uptake.  The white colonies 
each produced more white colonies and the blue colony produced more blue colonies.  
One colony from each of the white colony restreaks was added to 3 separate sterile tubes 
with 6 mL LB containing 50 µg/mL kanamycin and 7 µg/mL gentamycin.  The bacmid 
DNA was collected using ethanol precipitation.  Nanodrop was used to determine the 
concentrations of bacmid for each of the clonal isolate. 
 M13 polymerase chain reactions (PCR) were used to check for transposition of 
the PKG Iα E292A into the bacmid (Bac-to-Bac Baculovirus Expression System).  The 
reactions were set up and incubated in a thermocycler (Table 1 and Table 2). 
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Table 1: PCR reactions mixtures to test for bacmid insertion.  FP stands for forward primer and RP for 
reverse primer. 
Reagent E292A (1) E292A (2) E292A (3) 
[Bacmid] (ng/µL) 430.7 445.8 448.3 
Template (µL) 0.697 0.673 0.669 
ddH2O (µL) 22.32 22.33 22.33 
DreamTaq 2x (µL) 25 25 25 
5µM M13 FP (µL) 1 1 1 
5µM M13 FP (µL) 1 1 1 
Total (µL) 50 50 50 
 
Table 2: Thermocycler conditions for PCR to test for bacmid insertion. 
Step Temperature (˚C) Time (min) Description 
1 95 1:30 Hot Start 
2 95 0:45 Denaturation 
3 50 0:45 Annealing 
4 68 5:00 Extension 
5 Go to step 2, 30x  Cycle 
6 68 7:00 Final Extension 
7 4 Forever Storage 
 
 
 The first amplification of the virus was set up in a 6-well plate.  Sf9 cells were 
added to the plate at 0.9x106 cells per well.  The media was replaced with Graces and the 
cells were allowed to recover.  3 µg and 6 µg bacmid as well as a control containing no 
bacmid were added in duplicates to separate wells in the plate.  200 µL of a mixture of 
the appropriate bacmid and cellfectin were added to the wells.  The plates were 
periodically checked until the cells had begun to lyse.  At this point, the cells were 
scraped off the bottom of the well and the supernatant containing the amplified bacmid 
was collected. 
 For the second amplification, 15 mL of cells Sf9 at 1.0x106 cells/mL were added 
to a 75 cm2 flask.  300 µL of the first amplification virus was added to the cells and this 
was incubated at 27˚C until the cells had begun to lyse.  At that point, the cells were 
scraped off the bottom of the flask and the supernatant containing the amplified bacmid 
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was collected.  For the third amplification, 2 mL of the second amplification virus was 
added to a flask containing 40 mL of Sf9 cells at 1.0x106 cells/mL.  This was shaken at 
27˚C until the cells had begun to lyse.  At this point, the supernatant containing the 
amplified bacmid was collected. 
 The third amplification virus was used in expression trials.   40mL of cells at 
1.2x106 cells/mL were used for each ratio.  The ratios of mL virus to mL cells tested were 
1:100, 1:500, 1:1000, and 1:10000.  1mL samples were collected every 24 hours, starting 
at 0 hours, for 96 hours.  The samples were analyzed with SDS-PAGE and western blot.  
This showed the highest protein production at 96 hours with a ratio of 1:500.  These 
values were used to determine the ratio and time for the full expression. 
 For the PKG Iα E292A expression, 250mL of cells were mixed with 750 mL of 
serum-free media with lipids, gentamycin, and pluronics.  2 mL of the third amplification 
virus was added to reach a ratio of 1:500.  This was shaken at 27˚C for 96 hours.  At this 
point, the cells were collected by centrifugation at 500xg for 20 minutes, resuspended in 
lysis buffer, frozen with liquid nitrogen, and stored at -80˚C.  
 The extraction of these cells was done in a similar way to the E. coli extractions.  
The only difference was the French Press step was done at a PSI of over 500.  After the 
three dialysis steps, the protein was concentrated to 1.35 mg/mL.  The concentrated 
protein was separated into aliquots, frozen in liquid nitrogen, and stored at -80˚C. 
Surface Plasmon Resonance (SPR) 
 SPR experiments were carried out on each of the different protein segments, PKG 
Iα E292A, PKG Iα 78-326, and PKG Iα 78-356 to characterize the binding interactions 
with cGMP and cAMP.  The buffer used contained 50 mM MES pH 6.9, 150 mM NaCl, 
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1 mM TCEP, and 0.05% Tween 20.  The PKG was covalently bound with a 
heterobifunctional crosslinking to the gold-dextran chip using a 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride) (EDC) and N-hydroxysuccinimide 
(NHS) mixture.  Ethanolamine was used to coat any of the binding sites that were not 
bound to PKG.  The binding interactions were tracked between PKG and cGMP at 
concentrations from 10 nM to 500 µM, as well as between PKG and cAMP at 
concentrations from 500 nM to 10 mM.  Each concentration was tested three times. 
Kinase Assay 
 The phosphotransferase activity of PKG Iα E292A was determined using a 
radioactive phosphorous-32 kinase assay.  The activity was measured by testing the 
counts per minute after the reaction using liquid scintillation.  The 100 µL reactions were 
carried out at 30˚C for 1.5 minutes.  The reactions had 10 µL W-15 substrate, 50mM 
MES pH 6.9, 1 mg/mL BSA, and 10 mM DTT.  W-15 is a synthetically developed target 
for phosphorylation by PKG9.  The incorporation of radioactive phosphate onto W-15 
was measured.  In each of the reactions for PKG Iα E292A, 10.8 ng of protein was added.  
The control PKG data used for these experiments was wild type PKG Iα isolated in the 
same way as the PKG Iα E292A sample.  The reactions were started with radioactively 
labeled ATP.  After the incubation time, 15µL of the reactions were spotted onto 1 by 1 
cm filter paper squares.  These squares were washed with 0.2% phosphoric acid to 
remove any of the excess radiation and dried.  The radioactivity of these squares was 
determined using liquid scintillation counting.  Concentrations of cGMP ranging from 4 
nM to 4 µM were tested.  Each reaction was run in duplicate. 
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Acetonitrile Precipitation 
 An acetonitrile precipitation was used to determine the ratio of cGMP binding to 
PKG Iα E292A.  A sample of PKG Iα ∆53 was used as a control for the experiment.  
PKG Iα ∆53 exists as a monomer, therefore each peptide only binds 2 molecules of 
cGMP, while wild type PKG Iα binds 4 molecules of cGMP for every enzyme.  2 nmol 
PKG Iα E292A was combined with 5 molar equivalents of cGMP, and 1nmol ∆53 was 
combined with 3 molar equivalents of cGMP.  These were allowed to incubate on ice for 
15 minutes.  After this time, the samples were loaded onto two Zeba Spin Desalting 
Columns with a molecular weight cut off of 7 kDa (Thermo Fisher Scientific).  The 
column was subjected to centrifugation at 1500xg for 2 minutes.  At this point, the 
concentration of the flow through was determined using a Bradford assay.  This, and the 
volume of the samples were used to determine the amount of protein present after the 
column.   
 An equal volume of acetonitrile was added to each sample.  The samples were 
incubated on ice with periodic mixing by vortex for an hour.  They were then subjected to 
centrifugation at 20,000xg for 30 minutes to remove the precipitated protein.  The 
supernatant for each was transferred to a new tube and vacuum concentrated for 1.5 hours 
to increase the cGMP concentration.  At this point, the absorbance at 254 nm was 
determined by Nano Drop.  Beer’s law and the cGMP extinction coefficient of 16,900 
were used to the concentration of cGMP and determine the ratio of protein to cGMP in 
each sample. 
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Results 
Expression of PKG Iα E292A 
 Using the Bac-to-Bac Baculovirus Expression System (Invitrogen), the PKG Iα 
E292A construct was successfully expressed in Sf9 cells.  This system required 
transposition of the PKG Iα E292A gene into bacmid.  As determined by M13 PCR 
(Invitrogen), bands at approximately 4.5 kb indicated successful transposition of the PKG 
Iα E292A gene into all three clonal isolate bacmid (Figure 7).  
 
 
Figure 7: Agarose gel of PKG Iα E292A M13 PCR samples stained with SYBR safe viewed at 302 
nm.  All three samples indicated transposition of the gene into the bacmid. 
 
 The third clonal isolate bacmid was used to produce baculovirus in Sf9 cells.  The 
third amplification virus was used to infect Sf9 cells to express the PKG Iα E292A 
protein.  Western blot analysis probing for the hexahistidine-tagged PKG Iα E292A 
protein indicated that 1:500 ratio produced the highest amount of protein at 96 hours, 
therefore this condition was used in all subsequent expressions (Figure 8). 
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Figure 8: Western Blot of PKG Iα E292A test expression samples with Rabbit anti-his primary 
antibody and Goat anti-rabbit 680 secondary antibody.  The samples were reduced with TCEP.  The 
darkest band appears in the 1:500 ratio of virus to cells at 96 hours. 
 
 SDS-PAGE analysis indicated that PKG Iα E292A, purified by Ni IMAC column, 
was fully reduced post dialysis due to the presence of TCEP (Figure 9). The column 
elution was not reduced, so it was run on the gel in the form of a dimer.  A disulfide bond 
forms between the two protomers of the PKG Iα enzyme, keeping them bound even after 
boiling has removed the leucine zipper interaction10.  The dimeric protein formed a bond 
that remained around 150 kDa.  After dialysis with 1 mM TCEP, the protein had been 
reduced, now forming a band at around 75 kDa.  The protein purity was determined to be 
83.5% based on Image Lab lane analysis (Bio-Rad). 
 
 
Figure 9: SDS-PAGE of extraction samples of PKG Iα E292A from Sf9 expression stained with 
Instant Blue.  The protein had been successfully isolated and reduced after dialysis. 
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SPR of PKG Iα E292A 
 To gain insight about how the B site mutation of PKG Iα E292A affects the 
kinetics of cGMP binding, association, and dissociation, SPR experiments were carried 
out on this construct.  This produced an association rate (ka) value of 1.0x105 M-1*s-1 and 
a dissociation rate (kd) of 0.10 s-1 with residual standard deviation of 2.560 (Figure 10 A 
and B).  The equilibrium binding constant (KD) was determined to be 1.38 µM (Figure 10 
C). 
 
 
A	
B	
	 22	
 
Figure 10: Kinetic analysis of PKG Iα E292A with cGMP.  Response refers to SPR response in µRIU, 
the time is reported in seconds, and concentration is the cGMP concentration in M.  (A) Association and 
dissociation of cGMP.  (B) Residuals associated with the kinetics data.  (C) Binding affinity isotherm. 
 
SPR data for PKG Iα wild type (WT) from a previous lab experiment was used as 
a comparison.  The ka was calculated at 5.3x104 M-1*s-1, while a kd of 0.057 s-1 was found 
with residual standard deviation of 0.977 (Figure 11 A and B).  The KD was determined 
to be 1.35 µM (Figure 11 C). 
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Figure 11: Kinetic analysis of PKG Iα WT with cGMP.  Response refers to SPR response in µRIU, the 
time is reported in seconds, and concentration is the cGMP concentration in M.  (A) Association and 
dissociation of cGMP.  (B) Residuals associated with the kinetics data.  (C) Binding affinity isotherm. 
 
Kinetics data for cGMP binding to PKG Iα E292A was compared to cGMP 
binding data for WT PKG Iα produced in previous lab experiments.  The KD for PKG Iα, 
1.38 µM, was very similar to the WT enzyme at 1.35 µM (Table 3).  The mutation, 
despite interfering with B site cGMP binding, does not seem to have affected the affinity 
of the enzyme for cGMP.  The ka and kd rates for E292A, 1.0x105 M-1*s-1 and 0.10 s-1, 
were higher than those for WT, 5.3x104 M-1*s-1 and 0.057 s-1.  The mutant enzyme binds 
and dissociates with cGMP at a faster rate than the WT enzyme.  The KD was calculated 
from the isotherm as well as using the kinetics rates.  There was no significant difference 
between the values calculated by each method. 
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Table 3: Summary of surface plasmon resonance (SPR) data for wild type (WT) PKG Iα and the 
PKG Iα E292A mutant with cGMP.  Rate of association (ka), rate of dissociation (kd), and equilibrium 
constant (KD) for different segments of PKG with cGMP, as determined by SPR.  The KD was calculated 
for the isotherm and using the rate constants. 
PKG Construct  ka  (M-1*s-1) kd (s-1) KD (Isotherm) Kd (Rate) 
PKG Iα E292A 1.0x105 0.10 1.38 µM 1.0 µM 
PKG Iα WT 5.3x104 0.057 1.35 µM 1.1 µM 
 
Kinase Assay of PKG Iα E292A 
 The effect of reduction in cGMP binding sites on the phosphotransferase activity 
of PKG Iα E292A mutant was also studied.  A radioactive P-32 assay was used to 
determine how the mutant’s ability to phosphorylate target substrates differed from wild 
type PKG Iα.  PKG Iα ∆53 was used as the control in this experiment.  The logarithm of 
the cGMP concentration was graphed against the velocity of the reaction (Figure 12).  A 
nonlinear fit was used to determine the kinetics of this reaction.   
 
 
Figure 12: Graph of the logarithm of substrate (cGMP) concentration versus the velocity of the 
reaction based on a measuring the phosphotransferase activity of PKG Iα with radioactive P-32 
labeled ATP.  Based on data from two PKG Iα E292A trials and seven PKG Iα wild type (WT) trials. 
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 The nonlinear fit of the graph was used to determine the equilibrium association 
constant (KA), Hill coefficient, and maximal velocity (Vmax) for the two PKG Iα E292A 
samples and the seven PKG Iα WT control samples (Table 4).  The Hill coefficient is a 
measure of the coopertivity between binding sites in the enzyme. The Hill coefficient of 
1.57 is below the expected wild type value of 211.  The Hill coefficient is less than 2 but 
not as low as 1, a value indicating no coopertivity12.  This indicates there was some, but 
not total loss of coopertivity with the mutation.  PKG Iα E292A has a reduced 
equilibrium constant 112 nM instead of 243 nM for the control.  This indicates that 
cGMP seems to bind more strongly with the mutant enzyme.  Despite knocking out 
cGMP binding to the B site, the mutant enzyme is still able to carry out 
phosphotransferase reactions.  The Vmax of the reaction, 3.31 µmol*mg-1*min-1, is only 
slightly less than the WT Vmax, 4.63 µmol*mg-1*min-1.   
 
Table 4: Summary of the kinetics data obtained from the kinase assay.  This table gives the association 
constant (KA) and Hill constant for the two samples and the wild type (WT). 
PKG Iα sample KA (nM) Hill coefficient Vmax (µmol*mg-1*min-1) 
PKG Iα WT 243 1.76 4.63 
PKG Iα E292A 112 1.57 3.31 
 
Acetonitrile Precipitation of PKG Iα E292A with cGMP 
 The result of the acetonitrile precipitation was heavily obscured by a high salt 
concentration.  The cGMP concentration and stoichiometry could not be determined from 
the absorbance at 254 nm. 
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Expression and Extraction of PKG Iα 78-356 and PKG Iα 78-326 
In order to determine the effect of the switch helix motif on cGMP binding to the 
regulatory domain of PKG Iα, two regulatory domain constructs, with and without the 
switch helix, were expressed.  An expression trial of both PKG Iα 78-356 and PKG Iα 
78-326 was done in Rosetta E. coli cells to choose the conditions that produced protein.  
The samples for PKG Iα 78-356 had the highest expression with 1 mM IPTG induction 
after 3 hours (Figure 13).  The samples for PKG Iα 78-326 showed no protein expression 
in any of the time points. 
 
 
Figure 13: SDS-PAGE of PKG Iα 78-356 samples stained with Instant Blue.  The highest level of 
protein appeared after 3 hours with 1 mM IPTG induction. 
 
 Based on the test expression data, a 1 L expression of PKG Iα 78-356 was done.  
Samples for this expression were only taken at the beginning and end of the expression, 0 
hours and 3 hours.  There was no band in the expected location at 0 hours, but by the end 
of the induction period, PKG Iα 78-356 was expressed (Figure 14). 
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Figure 14: SDS-PAGE of Expression 5 (PKG Iα 78-356) samples stained with Instant Blue.  The 
protein was expressed by 3 hours of induction with 1 mM IPTG.  
 
An SDS-PAGE analysis on the extraction samples from the PKG Iα 78-356 
expression pellet, purified with a Ni IMAC column, indicated that the protein was 
isolated in the extraction (Figure 15).  After dialysis, the protein purity was calculated to 
be 79.3% using Image Lab Software (Bio-Rad). 
 
 
Figure 15: SDS-PAGE of extraction samples from Expression 5 (PKG Iα 78-356) stained with Instant 
Blue.  The protein had been successfully isolated.  The samples analyzed were post dialysis (PD), column 
elution (E), load flow through (FT), clarified lysate (CL), supernatant, and lysate. 
 
A 1 L expression of PKG Iα 78-326 was also done in E. coli.  Samples were taken 
at the beginning and end of the expression, 0 hours and overnight.  There was no band in 
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the expected location at 0 hours, but by the end of the induction period, a band for PKG 
Iα 78-326 had appeared (Figure 16). 
 
 
Figure 16: SDS-PAGE of Expression 4 (PKG Iα 78-326) samples stained with Instant Blue.  The 
protein was expressed by the overnight sample (ON). 
 
 PKG Iα 78-326 was extracted from this pellet.  Samples were taken throughout 
the extraction process and analyzed with SDS-PAGE (Figure 17).  The protein had been 
isolated in the elution.  However, there may have been some degradation beneath the 
main protein band. 
 
 
Figure 17: SDS-PAGE of extraction samples from Expression 4 (PKG Iα 78-326) stained with Instant 
Blue.  The protein had been successfully isolated.  The samples analyzed were post dialysis (PD), column 
elution (E), clarified lysate (CL), supernatant, and load flow through (FT). 
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Crystallization of PKG Iα 78-326 
 The structure of the PKG Iα regulatory domain without the switch helix has not 
been determined in the presence of cGMP.  This research attempted to crystallize this 
PKG Iα 78-326 and cyclic nucleotide interaction in order to reveal this unknown 
structure.  Successfully crystallized protein from this experiment could have been used in 
x-ray diffraction studies to characterize the crystal structure.  From there, the structure 
could be compared to the previously crystalized PKG Iα regulatory domain with the 
switch helix bound to cAMP2.  However, diffraction quality crystals were not produced 
in these experiments. 
 A Hampton Index (HR2-144) Screen was used to test for starting conditions on 
which to base further optimizations.  The most promising conditions from this screen 
were condition 15, 0.5M magnesium formate dehydrate with 0.1M HEPES pH 7.5, and 
condition 16, 0.3M magnesium formate dehydrate with 0.1M Tris pH 8.5.  These 
conditions both produced needles after two weeks.  The conditions were repeated and 
photographed with visible and ultraviolet (UV) light after 4 weeks.  The crystals could be 
seen in the visible light image (Figure 18).  They could also be seen in the UV image, 
indicating that they were composed of protein (Figure 19).  There was a bright ring 
around the well in the UV image.  This suggests that there was a large amount of protein 
remaining in solution.  Optimization could hopefully cause more of this protein to 
crystallize.  
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Figure 18: Visible light image of PKG Iα 78-326 with cGMP needles in the condition with 0.5M 
magnesium formate dehydrate and 0.1M HEPES pH 7.5.  The thin, dark lines in the center of the well 
are the protein needles. 
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Figure 19: UV image of PKG Iα 78-326 with cGMP needles in the condition with 0.5M magnesium 
formate dehydrate and 0.1M HEPES pH 7.5.  The light spots indicated that needles present in the 
condition were in fact made of protein. 
 
Additional attempts at optimization did not produce crystals.  Other optimization 
conditions produced more needles after two weeks.  Some of these needles developed 
into “sea urchin” shapes.  Low concentrations of magnesium formate, 0.1 to 0.2 M, more 
often lead to precipitation.  Higher concentrations of magnesium formate, 0.7 to 0.8 M, 
produced needles that took around 3 weeks to appear as opposed to the 2 weeks in the 
middle concentrations.  The needles grew at pH levels between 7.5 and 8.5.  The 
theoretical pI of PKG Iα 78-326 is around 5.7; therefore the protein seems to prefer being 
in a negative charge state.  Adding PEG 3350 caused the protein to precipitate.   
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 The PKG Iα 78-326 protein sample used in the crystallization was only 81% pure, 
a fact that may have hindered crystallography efforts.  High purity protein samples are 
needed to produce the regular crystal lattice necessary for x-ray diffraction13.  Ni IMAC 
columns do not produce completely pure protein samples; therefore there may have been 
contaminants that prevented the protein from forming single crystals.  For further 
optimization of crystallography techniques, a cAMP column could be used in the 
extraction to isolate a higher purity protein sample.  An increase in protein concentration 
could also lead to the formation of crystals.  Other crystallization experiments in the lab 
produced diffraction quality crystals at high PKG concentrations, so increasing the 
concentration above the 12-17 mg/mL used in this thesis could create diffraction quality 
crystals of this interaction. 
 
SPR of PKG Iα 78-326 and PKG Iα 78-356 
  The switch helix motif of the regulatory domain of PKG Iα exists directly next to 
the cGMP binding B site.  It was hypothesized that this motif would play a role in the 
kinetics of cyclic nucleotide binding.  In the interest of determining the effect of this 
interaction, SPR was used to analyze the two PKG Iα regulatory domain constructs, PKG 
Iα 78-326 and PKG Iα 78-356.  The interactions with cGMP were studied for both of 
these protein segments.  The interactions between PKG Iα 78-326 and cAMP were also 
observed to compare to cGMP binding. The rate of cyclic nucleotide association (ka), rate 
of dissociation (kd), and equilibrium constant (KD) were determined for each 
combination.  The KD values were calculated from the isotherm as well as using the 
	 33	
kinetics rates.  There was no significant difference between the values calculated by each 
method. 
The PKG Iα 78-356 and cGMP interactions were characterized using kinetics 
data.  This data produced a ka value of 1.8x104 M-1*s-1 and a kd of 0.29 s-1 with residual 
standard deviation of 1.492 (Figure 20 A and B).  The KD was determined to be 16.6 µM 
(Figure 20 C). 
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Figure 20: Kinetic analysis of PKG Iα 78-356 with cGMP.  Response refers to SPR response in µRIU, 
the time is reported in seconds, and concentration is the cGMP concentration in M.  (A) Association and 
dissociation of cGMP.  (B) Residuals associated with the kinetics data.  (C) Binding affinity isotherm. 
 
The kinetics of the associations between PKG Iα 78-326 and cGMP were 
determined by fitting the data from SPR.  This provided a ka value of 6.5x104 M-1*s-1 and 
a kd of 0.136 s-1 with residual standard deviation of 9.434 (Figure 21 A and B).  The KD 
was determined to be 2.54 µM (Figure 21 C). 
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Figure 21: Kinetic analysis of PKG Iα 78-326 with cGMP.  Response refers to SPR response in µRIU, 
the time is reported in seconds, and concentration is the cGMP concentration in M.  (A) Association and 
dissociation of cGMP.  (B) Residuals associated with the kinetics data.  (C) Binding affinity isotherm. 
 
The associations between PKG Iα 78-326 and cAMP were characterized using the 
SPK kinetics data. A ka value of 9.8x102 M-1*s-1 and a kd of 0.188 s-1 with residual 
standard deviation of 12.950 were found (Figure 22 A and B).  The KD was determined to 
be 200 µM (Figure 22 C). 
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Figure 22: Kinetic analysis of PKG Iα 78-326 with cAMP.  Response refers to SPR response in µRIU, 
the time is reported in seconds, and concentration is the cAMP concentration in M.  (A) Association and 
dissociation of cAMP.  (B) Residuals associated with the kinetics data.  (C) Binding affinity isotherm. 
 
 SPR data was used to compare the kinetics of cGMP binding between the 
regulatory domain constructs, PKG Iα 78-326 to PKG Iα 78-356.  The KD for PKG Iα  
78-356 at 16.6 µM was slightly higher than that of the other construct at 2.54 µM (Table 
A	
B	
C	
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5).  The switch helix motif does not seem to significantly increase the affinity of the 
regulatory domain for cGMP, and in fact seems to lower it.  The ka for PKG Iα 78-326 at 
6.5x104 M-1*s-1 is higher than for PKG Iα 78-356 at 1.8x105 M-1*s-1.  However, the kd for 
PKG Iα 78-326 of 0.136 s-1 is lower than 0.29 s-1 for the other construct.  This indicates 
that cGMP binds to the regulatory domain and dissociates at a faster rate when the switch 
helix is not present. 
 The kinetics of PKG Iα 78-326 binding with cGMP was also compared with the 
binding of the construct to cAMP.  The KD for cGMP, 2.54 µM, for this protein segment 
was much lower than that of cAMP, 200 µM, indicating a much higher cAMP affinity 
(Table 5).  Full length PKG Iα also has a much higher affinity for cGMP than cAMP.  
Therefore the switch helix may be not needed for cyclic nucleotide selectivity.  Cyclic 
AMP has a slightly higher kd, 0.188 s-1 versus 0.136 s-1 for cGMP, however the ka, 
9.8x102 M-1*s-1 is much lower than cGMP with 6.5x104 M-1*s-1.  It takes a much longer 
time for the association between PKG Iα 78-326 and cAMP to form than between PKG 
Iα 78-326 and cGMP.  Due to experimental error, the kinetics for the association between 
PKG Iα 78-356 and cAMP could not be determined.  PKG Iα 78-326 has kinetics data 
that is closer to wild type than PKG Iα 78-356. 
 
Table 5: Summary of surface plasmon resonance (SPR) data for the regulatory domain constructs.  
Rate of association (ka), rate of dissociation (kd), and equilibrium constant (KD) for different segments of 
PKG with cyclic nucleotides, as determined by SPR.  The KD was calculated for the isotherm and using the 
rate constants.  Kinetics values for PKG Iα 78-356 with cAMP were not determined (ND). 
PKG Construct  Cyclic 
nucleotide 
ka  (M-1*s-1) kd (s-1) KD 
(Isotherm)  
Kd (Rate) 
PKG Iα 78-326 cGMP 6.5x104 0.136 2.54 µM 2.1 µM 
PKG Iα 78-326 cAMP 9.8x102 0.188 200 µM 192 µM 
PKG Iα 78-356 cGMP 1.8x104 0.29 16.6 µM 16.1 µM 
PKG Iα 78-356 cAMP ND ND ND ND 
PKG Iα WT cGMP 5.3x104 0.057 1.35 µM 1.1 µM 
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Discussion 
 It is well known that the regulatory domain of PKG Iα consists of two cGMP 
binding sites, however the contribution of each binding site to overall PKG Iα activation 
has not been clearly characterized.  We expressed the mutant construct, PKG Iα E292A, 
to help address this gap in knowledge.  Each of the two binding sites contains a 
conserved FGE motif for cyclic nucleotide binding1.  The glutamate residue of this motif 
binds to the 2’-hydroxyl group on the ribose sugar of cyclic nucleotides7.  Mutating this 
residue in the B site interfered with this binding interaction.  The charged glutamate 
residue was no longer present in this binding site to allow interactions with cGMP.  
Despite this partial loss of cGMP binding, PKG Iα E292A had a cGMP affinity that was 
not significantly different from wild type PKG. Previous lab research determined that 
mutations of key residues in the A site that blocked cGMP lead to PKG Iα mutants that 
displayed only basal activity with cGMP14.  This current research shows that the B site 
mutation PKG Iα E292A maintains the ability for cGMP-dependent activation, with a 
Vmax slightly less than that of the wild type.  The Hill coefficient for the mutant is 
reduced from wild type but not reduced as low as one, indicating partial loss of 
coopertivity with this mutant.  The difference in activation between the A site mutant and 
B site mutant suggests that the enzyme only requires a functional A site for activation.  
Since the B site is not required for PKG activation, the role of the B site seems to instead 
be regulation of cGMP selectivity for the enzyme15.  This is supported by the fact that the 
B site is significantly more selective for cGMP over cAMP than the A site16. 
 In furtherance of the goal of understanding the A and B site contributions to PKG 
Iα activation additional regulatory domain mutants could be expressed.  The same 
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glutamate to alanine mutation could be incorporated into the FGE motif of the A site.  
This would allow for a direct comparison of the effect of loss of cyclic nucleotide binding 
to each of the cGMP binding sites.   
The result of the acetonitrile precipitation with cGMP was obscured by excess salt 
in the sample.  This experiment could be repeated, in hopes of determining the molar 
equivalents of cGMP bound to protein and revealing the number of sites where cGMP is 
able to bind.  Due to the reduced Hill coefficient seen in the mutant, it is expected that the 
mutant will bind only two molar equivalents of cGMP, indicating that binding to the B 
site has been interrupted.  This partial loss of coopertivity seems to indicate that there is a 
loss in cGMP binding sites. 
 In addition to the two cGMP binding sites, the regulatory domain contains a 
switch helix motif that may influence cyclic nucleotide binding1.  This domain sits 
adjacent to the B site of the regulatory domain, possibly allowing it to affect binding of 
cyclic nucleotides.  Two regulatory domain constructs, with (PKG Iα 78-356) and 
without the switch helix (PKG Iα 78-326), allowed for study of the effect of this motif on 
cyclic nucleotide binding kinetics.  This research determined that the presence switch 
helix domain decreased the affinity of the regulatory domain for cGMP.  Previous SPR 
research from this lab found the opposite, that the regulatory domain had a higher affinity 
with the switch helix17.  The similar constructs used in the previous research were 
dialyzed without a reducing agent, which may have affected cGMP binding.  This could 
be confirmed by preparing two samples using the same method with presence of reducing 
agent being the only difference.  The construct without the switch helix has kinetic 
properties that are much closer to the wild type enzyme than the construct with the switch 
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helix.  For the regulatory domain segment, the switch helix seems to have a detrimental 
effect on cGMP binding, decreasing the binding affinity.  The PKG Iα 78-326 construct 
showed a significant increase in KD for cGMP over cAMP binding.  Wild type PKG Iα 
has a much higher affinity for cGMP over cAMP, therefore it would appear the enzyme 
has high selectivity regardless of the presence of the switch helix18.   
 In order to provide a clearer picture of the effect the switch helix has on cyclic 
nucleotide binding, further attempts could be made at crystallizing the regulatory domain 
without the switch helix in the presence of cGMP.  Increasing the purity and 
concentration, as well continuing optimization around the initial needle-producing 
conditions could eventually produce diffraction quality crystals.  Once a crystal structure 
has been revealed, it can be compared to the previously crystallized domain with the 
switch helix in the presence of cGMP, to possibly provide an explanation for the 
differences in kinetics between the two constructs2. 
 The expression of constructs for each objective was done in different types of 
expression systems.  The full-length mutated protein PKG Iα E292A was isolated using 
an Sf9 expression system.  Eukaryotic cells are needed to phosphorylate a key tyrosine 
residue in order for the full-length construct to have phosphotransferase activity.  The two 
regulatory domain constructs, PKG Iα 78-356 and PKG Iα 78-326, did not contain this 
residue; therefore they could be expressed in E. coli.  Since these constructs do not 
contain the catalytic domain, they cannot be active, even when purified in Sf9 cells. 
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Supplemental Figures 
 
Supplemental Figure 1: Magnesium formate dehydrate and PEG 3350 optimization screen for 
crystallization of PKG Iα 78-326 with cGMP.  All of these conditions had 0.1 M Tris pH 8.0 buffer.  
Needles grew under the 1:1 ratio with 0.3 M to 0.5 M magnesium formate dehydrate, and 2:1 with 0.3 to 
0.6 M magnesium formate dehydrate, and 1:2 with 0.3 M magnesium formate dehydrate.  Most of the PEG 
3350 wells had precipitation and the one that did not, 5% PEG 3350 and 0.4 M magnesium formate 
dehydrate, was clear. 
 
 
 
 
 
	 45	
 
Supplemental Figure 2: Optimization screen for crystallization of PKG Iα 78-326 with cGMP.  This 
plate template was used for two different plates, one with 0.1 M HEPES pH 7.5 as buffer and the other with 
0.1 M Tris pH 8.5 as buffer.  Magnesium formate dehydrate was varied with the ratio of protein to well 
solution.  The Hampton Research (HR) solution was reagent #15 for the first plate and #16 for the second 
plate.  Plate 1: Needles grew under the conditions 0.1 M HEPES pH 7.5 with 0.5 M magnesium formate 
dehydrate and a 1:1 ratio.  They also appeared with 0.1 M HEPES pH 7.5, 0.7 M and 0.8 M magnesium 
formate dehydrate, and a 2:1 ratio.  All of the controls produced needles.  Plate 2: Needles grew with a 2:1 
ratio containing 0.1 M Tris pH 8.5 and 0.5 M, 0.7 M, or 0.8 M magnesium formate dehydrate.  All of the 
controls on this plate produced precipitation. 
 
 
 
 
	 46	
 
Supplemental Figure 3: pH optimization screen for crystallization of PKG Iα 78-326 with cGMP. 
Needles grew under the conditions 0.1 M HEPES pH 7.5 with 0.3 M, 0.4 M, and 0.5 M magnesium formate 
dehydrate. 
 
